Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG or PTCy vs CNI-MTX for GVHD Prophylaxis
NCT03602898Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Planned start Jun 2021; status: withdrawn.
02
Drugs
antithymocyte globulin rabbitcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03602898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602898.